Welcome to our dedicated page for DEXCOM SEC filings (Ticker: DXCM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
DexCom, Inc. filings document formal disclosures for its continuous glucose monitoring and glucose biosensing business. Recent 8-K reports cover quarterly and annual financial results, preliminary financial outlook, revenue by geography, operating income, non-GAAP measures, and exhibits containing earnings releases.
Dexcom proxy and governance filings address annual meeting matters, board composition, committee assignments, director independence, executive compensation, pay-versus-performance disclosures, equity awards, indemnity arrangements, and leadership-related compensation terms. The filing record also reflects material-event reporting for board appointments and other governance changes.
DEXCOM INC (DXCM) executive Sadie Stern, EVP Chief People & Culture Officer, reported selling 2,565 shares of Common Stock on August 27, 2026 at $88.37 per share in an open-market transaction. The sale was executed under a pre-established Rule 10b5-1 trading plan adopted on May 28, 2026. After this sale, Stern holds 126,043 shares directly, including 71,903 unvested restricted stock units that are scheduled to vest in tranches through March 8, 2029.
DexCom, Inc. (DXCM) received a Rule 144 notice from officer Sadie Stern covering a potential sale of common stock. The notice lists 2,565 shares of DexCom common stock to be sold through Morgan Stanley Smith Barney LLC on NASDAQ, with an aggregate value of $226,669.05 and a proposed sale date of 08/27/2026. The shares trace to restricted stock originally acquired from the issuer, including 1,874 shares acquired on 03/08/2024 and 691 shares acquired on 12/15/2023.
DEXCOM INC (DXCM) reported that President, CEO, and Director Jacob Steven Leach had 1,451 shares of common stock withheld on 2026-08-22 to cover tax withholding and remittance obligations in connection with the net settlement of restricted stock units; this is explicitly stated not to be a market sale. After this withholding, he holds 418,908 direct shares, including 142,836 unvested restricted stock units with grants from March 8, 2024, 2025, and 2026 that vest through March 8, 2029. He also has 47,296 shares held indirectly through the Gregg Family Grandchildren's Trust, with his spouse serving as trustee.
DEXCOM INC (DXCM) reported that EVP and Chief Financial Officer Jereme M. Sylvain had 1,451 shares of common stock withheld on 2026-08-22 to satisfy tax withholding and remittance obligations tied to the net settlement of restricted stock units; this was not an open-market sale. After this withholding, he holds 150,390 shares directly, including 87,094 unvested restricted stock units with grants on March 8, 2026, 2025 and 2024 that vest through dates extending to March 8, 2029.
DEXCOM INC (DXCM) reported that executive officer Michael Jon Brown had 1,451 shares of common stock withheld on August 22, 2026 to cover tax withholding and remittance obligations in connection with the net settlement of restricted stock units. This was not an open-market sale. After this withholding, Brown directly holds 101,502 shares of Dexcom common stock, including 71,903 unvested restricted stock units that vest in tranches from March 8, 2024 through March 8, 2029.
DEXCOM INC (DXCM) reported that executive officer Sadie Stern, EVP Chief People & Culture Officer, had 1,451 shares of common stock withheld on August 22, 2026 to cover tax withholding and remittance obligations in connection with the net settlement of restricted stock units; this was not an open-market sale. After this withholding, Stern directly holds 128,608 shares of Dexcom common stock, including 71,903 unvested restricted stock units that vest on various schedules through March 8, 2029.
DEXCOM INC (DXCM) Executive Chair Kevin R. Sayer reported open-market sales of a total of 26,756 shares of common stock on August 20, 2026, in three transactions at weighted average prices of about $89.71, $90.78, and $91.41. These sales were made under a Rule 10b5-1 trading plan adopted on February 18, 2026. Sayer continues to hold equity awards, including 106,972 unvested restricted stock units with grants from 2024–2026 that vest through dates in 2027 and 2028.
DEXCOM, INC. (DXCM) received a Rule 144 notice from Kevin R. Sayer covering a proposed sale of 26,756 shares of common stock through Morgan Stanley Smith Barney LLC, with an indicated aggregate market value of $2,408,240.67 and an anticipated sale date of 08/20/2026. The shares derive from restricted stock acquired from the issuer on 01/28/2025. The notice also lists prior sales over the past three months.
DEXCOM INC executive Michael Jon Brown, EVP Chief Legal Compliance Officer, reported selling 1,700 shares of common stock on August 14, 2026 at $91.93 per share in an open-market transaction under a pre-arranged Rule 10b5-1 Plan. Following this sale, he directly holds 102,953 shares, including 74,753 unvested restricted stock units that are scheduled to vest in tranches through March 8, 2029.
Michael Brown filed a Form 144 to potentially sell 1,700 shares of DXCM common stock through Morgan Stanley Smith Barney LLC Executive Financial Services, with an estimated aggregate market value of $156,281.00 as of 08/14/2026. The filing also lists prior sales of 1,700 shares each on 05/15/2026 for $101,847.00, on 06/15/2026 for $128,435.00, and on 07/15/2026 for $126,514.00.